title: [Idiopathic overactive bladder and BOTOX(®): Literature review].
abstract: OBJECTIVE
  Systematically review literature on the efficacy and tolerability of botulinum toxin A (onabotulinumtoxineA, BOTOX(®), Allergan, CA, USA) in refractory idiopathic overactive bladder (iOAB) METHODS: Pubmed search on the efficacy, toxicity and adverse events of onabotulinumtoxinA in clinical trials only with level 1 and 2 evidence.
  
  
  RESULTS
  Eleven controlled randomised trials have been selected, of which 3 phase III trials. The studies published data of 1008 patients with refractory iOAB treated with onabotulinumtoxineA. In the phase II and III trials, doses from 50 U to 300 U have been evaluated; more than half of the patients (n = 676) with 100 U. In the 2 main phase III trials, onabotulinumtoxinA has demonstrated to be more efficient compared to placebo on continence, symptoms and quality of live (QoL). Urodynamic results, reported in the phase II trials, demonstrated higher changes compared to placebo only from dose 100 U on, although not always significant. Adverse events (urinary retention, dysuria, urinary tract infection) were easily treated and did not influence patient's QoL.
  
  
  CONCLUSIONS
  Intradetrusor injections of onabotulinumtoxinA (BOTOX(®)), a minimally-invasive procedure, seem to be efficient and well tolerated in the treatment of refractory iOAB.
authors: Service d'urologie, hôpital de Rangueil, 1, avenue du Professeur-Jean-Poulhès, TSA 50032, 31059 Toulouse cedex 9, France.
authors: X
authors: X
authors: Gamé
authors: Service de chirurgie urologique et transplantation rénale, CHU de la Conception, Aix-Marseille université, 147, boulevard Baille, 13005 Marseille, France.
authors: G
authors: G
authors: Karsenty
authors: Service d'urologie, centre hospitalier Lyon Sud, 165, chemin du Grand-Revoyet, 69495 Pierre-Bénite, France.
authors: A
authors: A
authors: Ruffion
authors: Service de rééducation neuro-urologique, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
authors: G
authors: G
authors: Amarenco
authors: Service d'urologie, hôpital Pellegrin, place Amélie-Raba-Léon, 33076 Bordeaux cedex, France.
authors: P
authors: P
authors: Ballanger
authors: Service d'urologie, hôpital de la Pitié-Salpétrière, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France.
authors: E
authors: E
authors: Chartier-Kastler
authors: Service de gynécologie, CHRU de Lille, rue Eugène-Avinée, 59037 Lille cedex, France.
authors: M
authors: M
authors: Cosson
authors: Service d'urologie, CHRU Carémeau, rue du Professeur-Debré, 30029 Nîmes cedex 9, France.
authors: P
authors: P
authors: Costa
authors: Service de gynécologie, CHRU Carémeau, rue du Professeur-Debré, 30029 Nîmes cedex 9, France.
authors: B
authors: B
authors: Fatton
authors: Service de gynécologie-obstétrique, hôpital Antoine-Béclère, AP-HP, 157, rue de la Porte-Trivaux, 92140 Clamart, France.
authors: X
authors: X
authors: Deffieux
authors: Service d'urologie, hôpital Tenon, AP-HP, 4, rue de la Chine, 75020 Paris, France.
authors: F
authors: F
authors: Haab
authors: Service d'urologie, hôpital Bichat, AP-HP, 46, rue Henri-Huchard, 75018 Paris, France.
authors: J-F
authors: JF
authors: Hermieu
authors: Service d'urologie, Hôtel Dieu, CHU de Nantes, 1, place Alexis-Ricordeau, 44093 Nantes cedex 1, France.
authors: L
authors: L
authors: Le Normand
authors: Service d'urologie, CHU, 1, place de l'Hôpital, 67000 Strasbourg, France.
authors: C
authors: C
authors: Saussine
authors: Service de médecine physique et de réadaptation, hôpital Raymond-Poincaré, AP-HP, 104, boulevard Raymond-Poincaré, 92380 Garches, France. Electronic address: pierre.denys@rpc.aphp.fr.
authors: P
authors: P
authors: Denys
mesh_terms: D065087:Acetylcholine Release Inhibitors / Q000627:therapeutic use*; D000465:Algorithms; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D006801:Humans; D053201:Urinary Bladder, Overactive / Q000188:drug therapy*
chemical_list: D065087:Acetylcholine Release Inhibitors; D019274:Botulinum Toxins, Type A
keywords: Anticholinergics; Anticholinergiques; Botulinum toxin type A; Hyperactivité vésicale; Idiopathic; Idiopathique; Overactive bladder; Refractory; Réfractaire; Toxine botulinique de type A